' 
Supplement Facts
Serving Size: 3 Softgels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%**
Total Carbohydrate
2 g
1%**
Protein
less than 1 g
Reducol Plant sterols/stanols (as esters)††
900 mg
*
Pantethine (Pantesin)
300 mg
*
The product is found useful for the following medical conditions
High Cholesterol details
SCIENTIFIC SCORE
Likely Very Effective
Based on 1 Research
9.5
USERS' SCORE
Good
Based on 40 Reviews
8.7
9.5
Evinacumab dramatically reduces cholesterol
Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia.
Most Relevant Research
We explored the effectiveness of Evinacumab, a monoclonal antibody recently approved for treating severe high cholesterol. Our focus was on a 16-year-old girl from North India diagnosed with homozygous familial hypercholesterolemia (HoFH) at the tender age of two. Despite her long-standing battle with high cholesterol, traditional treatments, including medications and lifestyle changes, failed to bring her cholesterol levels down to the recommended guidelines.
Genetic testing confirmed that she had a significant mutation affecting her LDL receptor, contributing heavily to her condition. Her LDL cholesterol levels hovered around 320 mg/dL even after trying the maximum doses of established medications. As her health deteriorated, necessitating aortic valve replacement surgery, we introduced Evinacumab into her treatment regimen. What we observed was truly remarkable; her LDL cholesterol dropped by over 76%, reaching a level of 82 mg/dL that has remained stable over the last four months.
This case highlights Evinacumab as a promising option for managing patients with HoFH, especially for those who have not responded to existing therapies. This was also the first instance of a child in India receiving Evinacumab for this condition, potentially setting a precedent for future treatments.
Genetic testing confirmed that she had a significant mutation affecting her LDL receptor, contributing heavily to her condition. Her LDL cholesterol levels hovered around 320 mg/dL even after trying the maximum doses of established medications. As her health deteriorated, necessitating aortic valve replacement surgery, we introduced Evinacumab into her treatment regimen. What we observed was truly remarkable; her LDL cholesterol dropped by over 76%, reaching a level of 82 mg/dL that has remained stable over the last four months.
This case highlights Evinacumab as a promising option for managing patients with HoFH, especially for those who have not responded to existing therapies. This was also the first instance of a child in India receiving Evinacumab for this condition, potentially setting a precedent for future treatments.
8.8
Cholesterol normalised
Most Useful Review
The result is positive. After two months of taking it alongside other supplements like rice, phytosterols, and omega, my cholesterol, which was critical, became normal. Omega and rice alone didn’t work. My husband also refused statins (which he had taken for three years) and his indicators are now normal.
Leg Cramps details
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Good
Based on 4 Reviews
8.7
10
Completely eliminated cramps
Most Useful Review
Great for leg cramps caused by statins! This truly works if you experience leg cramps while on a statin. It seems that statins tend to deplete the body's CoQ10. I began with 100 mg, but when that did not alleviate my leg cramps, my doctor advised increasing it to 200 mg, which utterly rid me of my leg cramps. Definitely worth the investment to stay on statins for cholesterol reduction.
Migraine details
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
USERS' SCORE
Good
Based on 3 Reviews
8.6
9
MEDI0618 shows promise for migraines
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.
Most Relevant Research
We observed the potential of MEDI0618, a targeted monoclonal antibody, in treating migraine by focusing on a receptor known as protease-activated receptor 2 (PAR2). This study analyzed how the antibody impacted migraine-like symptoms in various preclinical models, including both human and rodent systems.
Through a series of experiments, we found that MEDI0618 demonstrated a strong binding ability to human PAR2, effectively preventing increases in cell calcium levels triggered by certain enzymes. This suggests that MEDI0618 could play a key role in blocking pain mechanisms associated with migraine without affecting other related receptors.
The antibody was tested in several conditions simulating migraine pain, involving both chemical triggers and stress. Remarkably, MEDI0618 was effective in reducing headache-like pain across various models, including those not dependent on CGRP (calcitonin gene-related peptide), which is typically targeted in migraine therapies.
Although the findings are promising for the prevention of migraine attacks, it's important to note that MEDI0618 did not show effectiveness in alleviating post-traumatic headache pain from brain injury. Overall, this research highlights MEDI0618 as a potentially innovative treatment option for people suffering from migraines, especially those experiencing CGRP-independent episodes.
Through a series of experiments, we found that MEDI0618 demonstrated a strong binding ability to human PAR2, effectively preventing increases in cell calcium levels triggered by certain enzymes. This suggests that MEDI0618 could play a key role in blocking pain mechanisms associated with migraine without affecting other related receptors.
The antibody was tested in several conditions simulating migraine pain, involving both chemical triggers and stress. Remarkably, MEDI0618 was effective in reducing headache-like pain across various models, including those not dependent on CGRP (calcitonin gene-related peptide), which is typically targeted in migraine therapies.
Although the findings are promising for the prevention of migraine attacks, it's important to note that MEDI0618 did not show effectiveness in alleviating post-traumatic headache pain from brain injury. Overall, this research highlights MEDI0618 as a potentially innovative treatment option for people suffering from migraines, especially those experiencing CGRP-independent episodes.
8.8
Reduced migraine severity
Most Useful Review
I've been taking these for years as directed by my neurologist to reduce the frequency and severity of my migraines. It took a good year to see the effect, but within three months, I also noticed a decrease in my Chronic Fatigue Syndrome symptoms, which was a delightful surprise. It's essential to maintain the regimen to ensure continued migraine relief.
